Providers

Procalcitonin test demand from the emergency department is growing, necessitating the implementation of strategies to address overuse. Successful interventions must be based on information technology.

This qualitative study on primary care physicians yielded suggestions that can inform the design of an effective lung cancer screening decision aid tool and implementation into the electronic health record.

This study quantified the trends over time in utilization of, spending on, and access to CT fractional flow reserve, the first artificial intelligence (AI)–enabled clinical software reimbursed by Medicare.

A real-world study assessed the impact of cannabis-based medicinal products on health-related quality of life in patients with multiple sclerosis (MS).

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

In this interview ahead of the 2024 American Society of Clinical Oncology annual meeting (ASCO), Ravin Ratan, MD, MEd, The University of Texas MD Anderson Cancer Center, discusses study data he is excited to hear more about on the combination of trabectedin and low-dose irinotecan for relapsed/refractory Ewing sarcoma.

Findings from a retrospective study suggested a possible causal relationship between prior infection and the development of hypersomnolence disorders such as narcolepsy and idiopathic hypersomnia, but more research is needed.

According to new research from Jordan, patients with both heart failure (HF) and diabetes had a higher prevalence of HF with preserved ejection fraction (HFpEF), elevated cholesterol, low-density lipoprotein, and impaired kidney function.

An analysis of 2 phase 3 trials supporting the use of pegcetacoplan (PEG) in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) assessed the benefits of this treatment compared with eculizumab (ECU) and supportive care measures.

A study using a large Korean health database found that people with a rare hair loss disorder called primary cicatricial alopecia were more likely to also have additional health problems like diabetes and high blood pressure compared with people who had other hair loss conditions or no hair loss at all.

Investigators explored the utility of unplanned resections, also called reresection, among patients who have soft tissue sarcomas.

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, discusses the clinical trials that influenced plasminogen's (Ryplazim; Kedrion Biopharma) FDA approval, as well as details valuable information for the treatment of patients with plasminogen deficiency.

Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed how the etiologies of hepatocellular carcinoma (HCC) and underlying liver function impact treatment approach.

Cardiovascular disease (CVD) risk was reduced by 1.2% in the intention-to-treat analysis and 5% in the per protocol analysis for adults aged 75 and older.

A retrospective study of over 100 pediatric and adolescent patients showed that providing virtual training for insulin pump use was both safe and effective.

However, investigators said there is some evidence suggesting attention-deficit/hyperactivity disorder may be more common in certain age groups of children with hemophilia.

In the final part of our interview with Binod Dhakal, MD, lead investigator of the CARTITUDE-4 study, he looks to the future of earlier treatment for relapsed/refractory multiple myeloma.

Patients who took the weekly glucagon-like peptide 1 (GLP-1) receptor agonist were 21% less likely to experience major kidney disease events and 29% less likely to die due to cardiovascular causes.

Newly published findings from the pivotal phase 3 BE HEARD I and BE HEARD II trials demonstrated that bimekizumab was well tolerated and produced clinically meaningful responses in patients with moderate to severe hidradenitis suppurativa.

A retrospective analysis found glucocorticoid treatment to reduce comorbidities in adults with Duchenne muscular dystrophy (DMD) and assessed the relationship between anthropometric measures and respiratory function and functional abilities.

The data refute the rapid-onset gender dysphoria hypothesis by showing that the initially higher depressive symptoms reported by youths transitioning from cisgender to transgender or gender diverse were not significant after accounting for exposure to LGBT violence, the researchers wrote.

Although an aerobic cooldown indeed lowers blood glucose levels in adults with type 1 diabetes after fasted exercise, by itself, the impact it has on hyperglycemia is insignificant.

From 2015 to 2020, the number of patients opting for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) over redo surgical aortic valve replacement (SAVR) rose significantly, from 35.3% to 62.5%.

A 68-year-old man was diagnosed with ocular myasthenia gravis after presenting with double-vision and photophobia.

Investigators continue to seek more information on how to optimally integrate treatment with tyrosine kinase inhibitors (TKIs) into an established concurrent chemoradiotherapy regimen.

A new report finds secondary immunodeficiency disease (SID) also increases the risk of mortality in patients with B-cell malignancies.

Vamorolone (Agamree) is a first-in-class corticosteroid to treat Duchenne muscular dystrophy (DMD) in patients 2 years and older.

The FDA approved the first 2 biosimilars referencing aflibercept (Eylea). However, patent litigation has left it unclear when the biosimilars will come to market.

Patients taking semaglutide for a year saw significant improvements in exercise capacity and lost 2.9% more body weight compared with patients taking placebo.

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, continues her discussion on plasminogen deficiency type 1 by highlighting the recent FDA approval of plasminogen (Ryplazim; Kedrion Biopharma), the first treatment specifically indicated for this disorder.